Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 191.58% | 64.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 191.58% | 64.10% | |||
| Cost of Revenue | 21.39% | -0.21% | |||
| Gross Profit | 232.46% | 94.15% | |||
| SG&A Expenses | 11.38% | -4.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.85% | -6.72% | |||
| Operating Income | 100.38% | 25.85% | |||
| Income Before Tax | 63.08% | 8.13% | |||
| Income Tax Expenses | 3.14% | 354.93% | |||
| Earnings from Continuing Operations | 62.40% | 7.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.40% | 7.37% | |||
| EBIT | 100.38% | 25.85% | |||
| EBITDA | 101.70% | 26.79% | |||
| EPS Basic | 63.81% | 7.67% | |||
| Normalized Basic EPS | 64.47% | 8.43% | |||
| EPS Diluted | 63.81% | 7.67% | |||
| Normalized Diluted EPS | 64.47% | 8.43% | |||
| Average Basic Shares Outstanding | 3.91% | 0.33% | |||
| Average Diluted Shares Outstanding | 3.91% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
